Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty

Richard D. Lentz, Jerry Bergstein, Michael W Steffes, David R. Brown, Konald Prem, Alfred F. Michael, Robert L. Vernier

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

Evaluation of pituitary gonadotropins, gonadal steroids, spermatogenesis, and menstrual function was undertaken in 32 patients (19 males and 13 females) treated with cyclophosphamide because of nephrotic syndrome. Patients were treated before, during, or after puberty. Evaluations took place after or in very late puberty. Spermatogenic dysfunction occurred in six of 15 boys who received the entire course before and during puberty and was probably dose related. Menstrual dysfunction did not occur following treatment of six prepubertal or pubertal girls, though only low total doses were used. Therapy after puberty was associated with spermatogenic dysfunction in all four boys, but did not cause menstrual dysfunction in any of seven women. Tentative guidelines are suggested that may minimize gonadal toxicity when cyclophosphamide is used in children with nephrotic syndrome. Factors of particular importance in the interpretation of gonadotropin determinations and of sperm counts in young cyclophosphamide-treated patients are discussed.

Original languageEnglish (US)
Pages (from-to)385-394
Number of pages10
JournalThe Journal of pediatrics
Volume91
Issue number3
DOIs
StatePublished - Sep 1977

Fingerprint Dive into the research topics of 'Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty'. Together they form a unique fingerprint.

Cite this